Cancer Drugs - Statistics

General Stats

Answer Stats

Hint	Answer	% Correct
estogen inhibitor	tamoxifen	75%
targets CD20 on B-cells	rituximab	67%
targets HER-2	Trastuzumab	67%
inhibitor of the tyrosine kinase domain of Bcr-Abl (philadelphia chromosome)	imatinib	50%
Beta tubulin assembly	vincristine	42%
targets VEGR (required for angiogenesis)	bevacizumab	25%
potent inhibitor of angiogenesis	thalidomide	25%
intercalates DNA, inhibits topo 2, chelates iron	doxorubicin	8%
topoisomerase II inhibitor (toxicity includes myelosuppression and 2nd leukemia)	etoposide	8%
targets CTLA-4	ipilmumab	8%
targets PD-1 on T-cells	nivolumab	8%
topoisomerase 1 inhibitor (DLT myelosuppression)	topotecan	8%
androgen inhibitor	bicalutamide	0%
binds DNA, resulting in single and double strand breaks following free radical formation and inhibition of DNA sythesis	bleomycin	0%
inhibits proteosome	bortezumab	0%
interacts with DNA at GC sites	dactinomycin	0%
GnRH antagonist that causes testosterone suppression	degarelix	0%
TKI that targets EGFR	erlotinib	0%
topoisomerase I inhibitor (active metabolite SN38)	irinotecan	0%
aromatase inhibitor	letrozole	0%
agonist at pituitary GnRH receptors; leads to testosterone suppresion	leuprolide	0%
intercalates DNA, inhibits topoisomerase 2, no free radical formation	mitoxantrone	0%
beta tubulin- no disassembly	paclitaxel	0%
inhibitor of CDK-4, CDK-6, and inactivates RB protein	palbociclib	0%
TKI that inhibits VEGF and RAF	sorafenib	0%
multiple receptor tryosine kinase inhibitor (inhibits VEGFR, PDGFR)	sunitinib	0%
mTor inhibitor	temsirolimus	0%
BRAF inhibitor	vemuramab	0%

Score Distribution

Percent of People with Each Score

Percentile by Number Answered

Your Score History

You have not taken this quiz